To address the value of surgery in patients with sporadic Zollinger-Ellison syndrome (ZES) with negative imaging studies. Background: Medical control of acid hypersecretion in patients with sporadic ZES is highly effective. This has led to these patients frequently not being sent to surgery, especially if preoperative imaging studies are negative, due, in large part, to existence of almost no data on the success of surgery in this group. Methods: Fifty-eight prospectively studied patients with sporadic ZES (17% of total studied) had negative imaging studies, and their surgical outcome was compared with 117 patients with positive imaging results. Results: Thirty-five patients had negative imaging studies in the presomatostatin receptor scintigraphy (SRS) era, and 23 patients in the post-SRS era. Patients with negative imaging studies had long disease histories before surgery [mean ± SEM (from onset) = 7.9 ± 1 [range, −0.25 to 35 years]) and 25% were followed for 2 or more years from diagnosis. At surgery, gastrinoma was found in 57 of 58 patients (98%). Tumors were small (mean = 0.8 cm, 60% <1 cm). The most common primary sites were duodenal 64%, pancreatic 17%, and lymph node (10%). Fifty percent had a primary-only, 41% primary + lymph node, and 7% had liver metastases. Thirty-five of 58 patients (60%) were cured immediately postoperatively, and at last follow-up [mean = −9.4 years; range, 0.2-22 years], 27 patients (46%) remained cured. During follow-up, 3 patients died, each had liver metastases at surgery. In comparison to positive imaging patients, those with negative imaging studies had lower preoperative fasting gastrin levels; had a longer delay before surgery; more frequently had a small duodenal tumor; less frequently had a pancreatic tumor, multiple tumors, or developed a new lesion postoperatively; and had a longer survival. Conclusions: Sporadic ZES patients with negative imaging studies are not rare even in the post-SRS period. An experienced surgeon can find gastrinoma in almost every patient (98%) and nearly one half (46%) are cured, a rate similar to patients with positive imaging findings. Because liver metastases were found in 7%, which may have been caused by a long delay in surgery and all the disease-related deaths occurred in this group, surgery should be routinely undertaken early in ZES patients despite negative imaging studies.
receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine) in the late 1970s to 1980s and later with the development of the long-acting proton pump inhibitors (PPIs) (omeprazole, lansoprazole, rabeprezole, esomeprazole, pantoprazole), which allowed onceor twice-a-day dosing in most patients. [1] [2] [3] The success of medical therapy, coupled with the fact that gastrinomas are frequently not localized preoperatively [4] [5] [6] and that in many patients with ZES the gastrinomas show indolent behavior, 7 has led to a number of groups recommending that surgical exploration not be routinely performed or that it should only be performed in patients in whom the preoperative imaging localizes a likely primary tumor. [8] [9] [10] [11] [12] [13] [14] [15] Recent studies show that the use of PPIs not only delays the diagnosis but also delays the time patients are sent to surgery; hence, patients present with more advanced disease. 3, 16 This latter recommendation has partially developed because of the lack of data on the efficacy of surgery in ZES patients with negative imaging studies. Some studies 17, 18 containing primarily sporadic ZES patients with positive imaging results have shown that surgical removal of the gastrinoma can increase survival by decreasing disease-related deaths, resulting in a decrease in the postoperative development of liver metastases, which are the major prognosticators of survival in ZES. 18, 19 However, no studies have specifically dealt with effectiveness of surgery in the negative imaging groups of patients with sporadic ZES.
In the present study, we have attempted to address this issue by comparing 229 ZES patients from our prospective study. The surgical results of 58 sporadic ZES patients with preoperative negative imaging studies [35 in the pre-somatostatin receptor scintigraphy (SRS) era, and 23 in the post-SRS era] were compared with the results of 117 patients with positive imaging studies operated on the same time period.
METHODS
Two prospective databases of patients who underwent surgery to remove gastrinoma and cure ZES were reviewed. 5, 19 One database focused on patients who underwent surgery at the Stanford University Hospital since 1996, and the other on patients who underwent surgery at the National Institutes of Health since 1981. The main outcome measures were overall survival, disease-related survival, and time to development of any recurrence and liver metastases.
The diagnosis of ZES was based on the measurement of an elevated fasting serum level of gastrin (>100 pg/mL), an elevated basal acid output (>10 mEq/h), and the results of secretin and calcium provocative tests. 20, 21 Basal acid output (BAO) and maximal acid output (MAO) were determined for each patient, using methods described previously. Briefly, each patient had an elevated fasting serum level of gastrin and a concomitant elevated basal acid output. Most patients also had an abnormal secretin test (>120-pg/mL increment in gastrin after intravenous administration of 2 U/kg of secretin). 21 These studies confirmed the diagnosis of ZES. After confirmation of the diagnosis, patients underwent detailed imaging studies [thin-slice emission computed tomographic views, 4, [22] [23] [24] [25] and in selected cases abdominal angiography to determine precise tumor localization and operability as described previously. In some patients, if SRS and conventional localization were equivocal, either selective venous sampling for gastrin gradients basally 26 or post-secretin injection and hepatic venous sampling 27 was used to regionally localize the tumor. 28 Patients underwent surgery to remove the tumor if they had no comorbid medical condition markedly limiting life expectancy, or they had imaging evidence of either operable localized tumor or no identifiable tumor. 17, 25, 29 In this particular study, patients with either preoperative imaging evidence of liver metastases or family history and biochemical evidence of MEN-1 were excluded, and only patients with sporadic ZES with either imaging localized or negative imaging gastrinomas were included.
A detailed history of disease was taken at first admission and past medical-surgical procedures as described previously. 6 Time from onset of symptoms to exploration was determined for all patients. The time of diagnosis of ZES was the time the diagnosis was first established by appropriate laboratory studies, when a physician established the diagnosis on the basis of clinical presentation or when the histological diagnosis was established. 6 The operative techniques have been described previously. 5, 18, 29, 30 The pancreas and duodenum were widely exposed by dividing the inferior border of the body and tail of the pancreas and performing an extended Kocher maneuver during which the right colon and hepatic flexure were mobilized away from the pancreas and duodenum. Intraoperative ultrasonography of the pancreas and duodenum was systematically performed on all patients. 31 The duodenum was routinely opened longitudinally and closed transversely in all patients unless a gastrinoma was located in the body or tail of the pancreas. 5 A detailed inspection for peripancreatic, periduodenal, or portohepatic lymph nodes was carried out, and these were routinely removed. Tumors in the pancreatic head were enucleated. Tumors in the pancreatic body and tail were resected with a distal pancreatectomy splenectomy. If a large pancreatic head tumor was present and could not be enucleated, a pancreaticoduodenectomy was performed. If liver metastases were present, they were biopsied and excised by either wedge resection or anatomical resection. Postoperatively, patients underwent evaluation for disease-free status immediately after surgery (ie, 2 weeks postresection), within 3 to 6 months postresection, and then yearly. 6, 25, 32, 33 Yearly evaluations included conventional imaging studies (CT, ultrasonography, MRI, and angiography, if necessary); SRS since 1994; assessment of fasting serum level of gastrin, secretin-stimulated gastrin level, and acid output. Complete disease-free status (or cure) is defined as normal fasting serum levels of gastrin, negative secretin test result, and no evidence of tumor on postoperative imaging studies including CT and SRS. 5, 6, 29, 33 A recurrence postresection was defined as occurring in a patient who was initially disease free but then lost the disease-free status on follow-up, which demonstrated positive imaging findings or recurrent elevated fasting serum gastrin levels. 25 All continuous variables were reported as mean ± standard error of the mean. Survival analysis was done using the Kaplan-Meier method and 2-group comparisons using log-rank tests. Proportions are compared statistically by the Fisher exact test. Statistical analyses were performed by means of the SAS statistical software package, and significance was defined as 2-tailed P value of less than 0.05.
RESULTS
A total of 339 patients with ZES were identified, including 110 patients with MEN-1 and 229 sporadic patients. This analysis excludes patients with MEN-1; of the 229 sporadic ZES patients, 58 had negative preoperative imaging, and those were compared with 117 patients with positive imaging studies who underwent the same operation. Of the negative imaging cohort, 35 patients were from the pre-SRS era and had negative conventional imaging studies (CT, MRI, ultrasonography) and angiography, whereas 23 were from the post-SRS period 23 and had both SRS and the imaging studies described for the pre-SRS group. Of the 58 negative imaging patients, 33 (57%) were men, with a mean age of 42.6 years and the onset or diagnosis of ZES at the age of 48.8 years, their main presenting symptom was upper abdominal pain, and none of these variables were different from those of the positive imaging cohort (Table 1 ). However, the proportion of the patients with prior abdominal surgery (10%) and acid-related surgery (3.4%) were significantly lower in the negative imaging group than in the positive imaging group (44% and 21%, respectively) ( Table 1 ). This was not true for hiatal hernia surgery, which was higher proportionally in the negative imaging group (8.6% vs 0.8%). The fasting serum gastrin level was significantly lower for the negative imaging group, but the delta secretin and the BAO were not different ( Table 1) .
Fifty-seven of 58 (98%) of the patients with negative imaging studies had gastrinoma excised at surgical exploration, and although there was a trend (P = 0.059), this was not different from the patients with positive imaging studies of whom 90.5% had their gastrinoma excised ( Table 2 ). Of the patients with negative imaging studies, significantly more tumors were found in the duodenum (64% vs 37%, P = 0.0008); furthermore, significantly fewer tumors were found in the pancreas (15.5% vs 30%, P = 0.039). In the negative imaging group, there were no truly extrapancreatic, extraduodenal tumors compared with 10.2% in the positive imaging group (P = 0.008) ( Table 2 ). The exact distribution of gastrinomas found at surgery in the preoperative negative imaging patients is shown in Figure 1 . Most are found in the first and second portions of the duodenum (61%), whereas another important group (29%) contained lymph nodes that are found in the area of the pancreatic head. There is a uniform distribution of pancreatic gastrinomas throughout the pancreas. The size of the negative imaging tumors is smaller than the ones that are imaged preoperatively (1 vs 1.9 cm). A significantly higher proportion of these tumors are less than 1 cm (62% vs 20.5%), and a significantly lesser proportion is greater than 3 cm (1.7% vs 18%) ( Table 2 ). Despite the fact that the imaging was negative, a similar proportion had biopsy-proven liver metastases (6.8%) as the positive imaging patients (7.7%). The surgical procedures and complications (34% both groups) were similar in the negative and positive imaging cohorts ( Table 3) . A higher proportion of negative imaging patients waited more than 10 years from the onset of ZES to surgery (38% vs 25%, P = 0.036). The procedures performed were similar in the 2 groups, except the negative imaging patients had a greater proportion of proximal pancreaticoduodenectomies (6.8% vs 0.8%, P = 0.024). The operative deaths were the same, with no deaths reported in the negative imaging group and 1 (0.8%) in the positive imaging group.
The mean postoperative follow-up is approximately 10 years, and it is similar between the 2 groups ( Table 4 ). The proportion of patients who are alive at last follow-up and had conversely diseaserelated deaths showed a trend to superiority in the negative imaging group (P = 0.062), but it did not reach statistical significance. The proportion of patients who are disease free is 48% in the negative imaging group and is not different from the 35% in the positive imaging group. There was no difference in the proportion of patients who developed liver metastases after surgery, nor the time to development of liver disease; however, the number of patients developing new imageable lesions after surgery was only 21% in the negative imaging group and 41% in the positive imaging group (P = 0.008). The overall and disease-related survival was not significantly different from each other for the negative imaging patients, but it was significantly better than the same results for the positive imaging patients ( NS * One patient in negative imaging group had l nephrectomy for renal cell cancer. In the positive imaging group, 3 patients had a colectomy for colon cancer, 8 patients had an appendectomy, 5 patients had hysterectomy, 5 patients had cholecystectomy, 2 patients had negative laparotomy for positron emission tomography, 2 patients had small bowel obstruction, 1 patient had renal cell cancer, and 1 patient had small bowel perforation after radiological procedure.
†Basal acid output data are shown for patients without previous acid-related surgical procedures and include data from 49 patients in the negative imaging and 95 patients in positive imaging groups. 34 †Other primary locations include in the positive imaging group: 13 patients with primary tumors in ovary (n = 1); liver (n = 4); pylorus (n = 2); heart (n = 1); common bile duct (n = 2); omentum (n = 2); and lung cancer (n = 1).
‡Unknown includes in the negative and positive imaging groups, respectively: 4 and 11 patients with only lymph node metastases; 0 and 2 patients with only liver metastases, found and determined as described in Methods, and 1 and 11 patients with no tumor found. .96 * One patient in the positive imaging group died postoperatively of a pulmonary embolus. †Complications for the negative and positive imaging groups include pancreatitis (5,3); abscess (1,10); fistula (2, 18) ; pneumonia (2,2); postoperative motility disorder (2,2); phlebitis (1, 5) ; wound infection (4,6); hepatitis (1,0); postoperative bleeding (0,1), respectively. and Fig. 2 ). Negative imaging patients had an overall 20-year survival rate of 71% compared with 58% for the positive imaging patients, and the disease-related survival rate was 88% compared with 73% (P = 0.015).
DISCUSSION
At the 100th annual meeting of the American Surgical Association in 1980, Dr Robert Zollinger, in the discussion of his paper on the 25-year appraisal of his surgery in patients with ZES, 35 
stated:
We have to convince our physician friends that it is time to recommend that every gastrinoma be considered a surgical problem. They should not treat the patient with cimetidine indefinitely. It is a basic principle to take out the malignant tumor rather than to treat the end result.
Unfortunately, several features of ZES/gastrinomas have led a number of groups not to heed Dr Zollinger's advice and instead to advocate over the intervening years a completely medical approach, Figure 2 .
†For the negative imaging patients during the follow-up [9.5 ± 0.72 (range = 0.1-21.8 years)] from surgery, 11 patients died of any cause (overall survival) ( Fig. 1 ) and 4 died of a disease-related cause (Fig. 1) .
‡For the positive imaging patients during the follow-up [11.6 ± 0.6 (range = 0.1-28.1 years)] from surgery, 38 patients died of any cause (overall survival) ( Fig. 1 ) and 20 died of a disease-related cause (Fig. 1) .
§The differences between the overall survival and disease-related survival were not significant (P = 0.069, HR = 2.56, 95 CI = 0.92-7.1) for the negative imaging patients. However, they were significantly (P = 0.015, HR = 1.93, 95 CI = 1.14-3.2) different from the positive imaging patients. or one in which only patients who had been imaged for possible primary tumors undergo surgical exploration for possible cure. [8] [9] [10] [11] [12] [13] [14] [15] The ZES/gastrinoma features that encouraged this approach included the development of highly successful medical treatment of the gastric acid hypersecretion 1, 2, [30] [31] [32] ; the failure to image primary tumors in 30% to 70% of patients in different series, especially those with duodenal primaries [4] [5] [6] 36, 37 ; the fact that only 20% to 30% of gastrinomas pursue an aggressive course 38, 39 ; and that, until recently, the lack of prospective studies showing surgery could cure a significant number of these patients effect the development of liver metastases or survival. 40 Other factors favoring a decrease in the use of early surgery for possible cure in these patients included a long delay in the diagnosis of ZES, which is a mean of more than 5 years in some studies, 12, 19, 20 and likely increasing with the widespread use of PPIs, 16 and the delay in time from diagnosis to surgery of 4 to 8 years in some studies. 19 Recent studies have dealt somewhat with a number of these points in that they report immediate postoperative cure rates in patients with sporadic ZES of 50% to 60% and long-term cure rates of 30% to 40%, 5, 6, 19 an increase in the survival of patients undergoing surgical resection 17 and a decrease in the development of liver metastases, 17, 18 which are the most important prognostic factor for survival. 7, 39 Nevertheless, a recent study, 3 concluding from an analysis of patients diagnosed and treated during different time periods, reports that these aforementioned factors leading to delays in surgery are still functional in that, at present, these patients are being operated on later in their disease course with more advance-stage disease in this era of PPI treatment. 5, 7, 19, 23, 26, 33, 36, 39, 41, 42 The present study attempts to address one of the important implicit premises of the avocation of recommending operation only for positive imaging patients (ie, that surgery is less effective in negative imaging ZES patients) by comparing results of 58 patients with negative imaging with 117 patients with positive imaging operated over the same time period. Although the study concludes that surgery in negative imaging patients is just as likely to find a primary gastrinoma, the cure rate is as high, and the survival is even better than that in the positive imaging patients, there are a few points that could question the result. First, one could argue that insignificant number of patients had endoscopic ultrasonography that has been identified as one of the best studies to localize pancreatic neuroendocrine tumors. 5, 37, 44 However, in this study, in the negative imaging patients, duodenal gastrinomas were much more frequent (4-fold) than pancreatic gastrinomas, which is similar to other recent studies. 5, [41] [42] [43] Numerous studies have reported that endoscopic ultrasonography does not show most duodenal gastrinomas, 5, 44 finding only 35% in 1 review of 5 series. 37 Furthermore, all of these patients had careful endoscopic examination of the duodenal area in an attempt to identify any submucosal gastrinoma. 5 In addition, intraoperative ultrasonography gives poor results in duodenal gastrinoma imaging. 42 This may be because the duodenum has a mixed background with solid, liquid, and gas in which it is difficult to detect sonolucent neuroendocrine tumors such as gastrinomas. Therefore, these data support the conclusion that even if endoscopic ultrasonography were performed prospectively on these patients, it would not have identified a significant additional number of patients preoperatively. Furthermore, it could be argued if SRS were performed on those operated on, before it became available, additional duodenal lesions might have been detected and therefore the results are not applicable at present, when the facility of SRS is available. These results cannot be completely refuted; however, 40% of our patients had negative SRS findings in the present study, and, furthermore, the SRS frequently missed small duodenal tumors and because most patients had small duodenal primaries, it would have been positive in less than 50% even if used. 4 Somatostatin receptor scintigraphy has been reported to be the single best preoperative localization study for gastrinoma. It has been able to detect approximately 30% of gastrinomas of less than 1-cm diameter, 64% between 1 and 2 cm, and 96% of those greater than 2 cm. Because, it is a total body examination, it is especially useful for ectopic (extrapancreatic, extraintestinal) gastrinomas. 4, 23 This study corroborates these results because 13 patients (10%) in the positive imaging group had extrapancreatic, extraintestinal gastrinoma in ectopic locations including the heart, liver, and ovary, whereas none in the negative imaging group had similar findings. This is the first study in ZES that has focused on negative imaging patients. A common question by patients and referring physicians is why perform surgery on these patients with negative imaging studies when they are so well controlled on PPIs? The demographic characteristics of patients with negative imaging studies are remarkably similar to those with positive imaging tumors except they have lower fasting serum gastrin levels and fewer prior surgical procedures for uncontrolled symptoms of ZES. Furthermore, they have a longer time interval from their disease onset to surgery, suggesting that the referring physicians were reluctant to allow them to have surgery. In some studies, 21 the level of fasting gastrin correlates with gastrinoma size or tumor burden; therefore, the finding of lower preoperative fasting gastrin levels in the negative imaging patients is consistent with our finding at surgery of smaller tumors in the majority of these patients. The fact that they have had fewer surgical procedures for complications of ZES is also consistent with smaller tumor burden. This was also demonstrated by the size of tumors removed during surgery that were significantly smaller in the negative imaging group. Furthermore, in this study, there was an equal probability to find tumor in the negative imaging group as in the positive imaging group. The location of the primary tumor in the negative imaging group was most often in the duodenum, suggesting that the critical maneuver to finding negative imaging gastrinomas is duodenotomy at the time of surgery. 5, 42 The negative imaging group had fewer other tumors, fewer pancreatic tumors, fewer unknown locations, and fewer greater than 1-cm tumors explaining the negative imaging, as radiographic imaging is mostly dependent on size. The extent of tumor in the negative imaging group is still very worrisome, as 4 had liver metastases and 34% had lymph node metastases and both of these can affect subsequent disease-related survival. 7, 17, 19, 39 Each of the deaths in the negative imaging patients occurred in patients with liver metastases. The time from onset to surgery was longer in the negative imaging cohort probably because of delay or procrastination related to the negative radiographic imaging. The extent of surgical operation was similar in the 2 groups, except more patients in the negative imaging cohort had Whipple procedures because of more extensive nodal disease with small duodenal primary tumors. The complications were identical, and only 1 surgical death was reported. The most important results are the long-term outcome data based on preoperative positive and negative imaging results. There is no difference in the development of liver metastases in the negative and positive imaging groups, but there is a higher overall development postresection of imaged lesions in the preoperative positive imaging group. There is better overall and disease-related survival and a trend to higher cure rate in the negative imaging group.
This study suggests that ZES patients with negative imaging studies can greatly 19 benefit from surgical exploration. Tumor is almost always found and removed with acceptable morbidity and minimal mortality. Surgeons doing these procedures should focus primarily on the duodenum and gastrinoma triangle, as most tumors will be found there. However, a complete exploration is necessary, as liver metastases and body/tail pancreatic tumors still occur, albeit less frequently. Furthermore, it is essential to routinely sample lymph nodes both in peritumoral areas and in the pancreatic head area, as this may increase the cure rate, has prognostic significance, and is the only means of detecting possible lymph node primary gastrinomas. 19, 34 Lymph node primary gastrinomas are controversial and may represent a missed duodenal primary with lymph node metastases as some suggest. 34 The nonimaged tumors are small in size and usually occur within the duodenum. A critical maneuver is duodenotomy that allows precise detection of the duodenal tumors. 5, [41] [42] [43] They are not ectopic, and they have a similar incidence of lymph node and liver metastases. This type of careful meticulous exploration and resection of preoperative negative imaging tumors should result in improved cure rate and improved long-term overall and disease-related survival. This happens because negative imaging is associated with a lower incidence of subsequent tumor recurrence.
DISCUSSANT
DR. MURRAY F. BRENNAN (New York, NY): Thirty years ago, as a new member of this organization, I first presented the experience from the National Institutes of Health on this disease. As Dr. Norton alluded to, at that time, we had a new drug called cimetidine, and we managed 26 patients with cimetidine alone. The dose required was 5.6 grams per day, which was 900 milligrams every four hours. For two of the patients whose 4 a.m. dose we stopped to measure their gastric acid, one bled and the other perforated, needing an emergency operation. The majority of the males experienced both gynecomastia and impotence.
They argue for early surgery based on the fact that 7% of the patients did have liver metastasis. That would be a reasonable argument if, they were cured. Despite finding 98%, only 60% were cured. Crucial to that argument is that the image-negative patients experienced a 20-year survival of 71%, compared to 58%, of image positive.
My observations and questions are the following: Why are so few of the sporadic people are not cured? Can that all attributed to unsuspected metastatic disease?
Is it possible that what you report is all due to lead time bias, i.e., by operating before the patient has a positive imaging, all you are doing is setting the clock back, as the long-term death rate is the same? As death from this disease is due to metastatic disease, does it not imply, because of the equal prevalence of liver metastasis that that would argue against your premise?
DR. JEFFREY ALLEN NORTON: So few patients are cured because of our inability to totally resect the tumor. We are not able to do it. We do not find all the lymph node metastases, or the liver metastases. The surgery is limited. Therefore, the cure rate is related to our inability to totally remove the tumor, which we are only able to do in about half the patients.
I think that if we performed more aggressive surgery, the curerate may improve, though it does not appear to be warranted because the survival rate is so good. I agree with you that there is a lead-time bias. In the imaging-negative patients, we can still find the gastrinoma, it is just smaller. We know where to look for them, we know what they feel like, and we are able to find and remove them. It has not greatly enhanced our ability to cure patients because they have occult distant disease.
DR. CHRISTOPHER ELLISON (Columbus, OH): Are you selective in this algorithm you developed? In other words, are you operating on everybody that is image negative? If they are image negative, do you go on and do additional testing, like selective arterial secretin stimulation?
DR. JEFFREY ALLEN NORTON: If ZES patients are imaging negative, we still recommend and offer surgery. We do not do secretin angiogram anymore because, when we did secretin angiogram previously, we always noted that the tumor was in the distribution of the gastroduodenal artery or the gastrinoma triangle. It is clear that the key area to look for tumors is the gastrinoma triangle.
The other point that we did not mention and that is very important, is that somatostatin receptor scintigraphy is able to image tumors that are not in the gastrinoma triangle. For example, we have seen intracardiac gastrinomas. We have seen primary tumors in the liver and the ovaries. It is important to exclude extra-duodenal and extra-pancreatic tumors as well.
DR. KEITH LILLEMOE (Boston, MA): There has been no mention of endoscopic ultrasound. Have you included that in your armamentarium in order to help find these lesions in advance?
Secondly, you noted that the percentage of patients having a Whipple was higher. You made mention that this was due to the fact that they had more nodal disease. Do you, in any cases, perform a "blind Whipple" without being able to find a specimen simply because of the high probability that the tumor will be located in the gastrinoma triangle?
DR. JEFFREY ALLEN NORTON: Endoscopic ultrasound (EUS) was not available when we initially started this study. It has become more available, but the studies are still negative in a significant proportion of patients. If you look at publications, about 60% of patients with Zollinger-Ellison syndrome will still receive negative endoscopic ultrasound. One of the reasons, we hypothesize, is that the duodenum does not have a very uniform background. In other words, endoscopic ultrasound is really good for the pancreas because it has a very solid echogenic appearance and the tumors appear sonolucent. In the duodenum, you have a mixed background of the wall, air, and liquid, so EUS is less able to image tumor.
The other point is that Dr. Imamura from Japan has actually done exactly what you said. He does secretin angiograms on everybody. If it is positive in the distribution of the gastroduodenal artery, he performs Whipple operations. I do not know his total results, but I think his data are excellent in the ability to find tumor and cure patients with ZES.
DR. PATRICIA DONAHOE (Boston, MA): As pediatric surgeons, we have opportunities to work with our developmental biology colleagues who describe the entity of homoeotic transformation of stomach-specific genes or pancreas-specific genes into the duodenum, along the anterior/posterior axis, such as Hox, sonic hedgehog, and bone morphogeneses factor genes. Have developmental genes been sequenced on the pancreas/stomach/duodenum of these patients? It might be of value to look at some of the elegant, early classical developmental biology studies.
DR. JEFFREY ALLEN NORTON: I think that is an excellent point. I am not aware of any studies you describe. We are currently doing some preliminary studies to determine which genes are important for this tumor. DISCUSSANT DR. L. MICHAEL BRUNT (St. Louis, MO): I noticed you also had a couple of tumors in the third duodenum, a very difficult spot to get to and localize. How did you find those tumors? Were some of those done as a part of the pancreaticoduodenectomy? DR. JEFFREY ALLEN NORTON: The tumors in that location, as you mention, are very difficult to find. We widely expose the duodenum, and we try to palpate the whole organ carefully, then we open the duodenum. We try to open it more toward the second and third portion so we can palpate inside and outside of the entire duodenum. It has been shown by Norman Thompson, which we corroborate, that duodenotomy or opening the duodenum, is the key maneuver to finding duodenal gastrinomas including those in the third and fourth portion.
DR. ROBERT BEAZLEY (Boston, MA): Dr. Brennan's comments on cimetidine gave me a historical "flash back." I recalled caring for a ZE patient in the early 1970s at the Surgery Branch (NIH) who had recently been started on cimetidine. His medicine clinical associate explained to me that in the future I would not be seeing ZE patients because of this new drug. About 72 hours later I took the patient to surgery for a perforation, which necessitated a Whipple resection. This was likely one of the very early failures Dr. Brennan referred to.
DR. JEFFREY ALLEN NORTON: I think that is an important point. You are correct. Cimetidine is ineffective, but the proton pump inhibitors are very effective for the control of the acid hypersecretion.
DR. RICHARD A. PRINZ (Evanston, IL): The time frame of the study was not clear to me. Obviously, it has occurred over many years. Imaging capability during this time period has really improved in all of the studies that you have utilized. What is your current approach with imaging, including the Imamura test and endoscopic ultrasound? How do you try to localize the tumors in these patients?
Secondly, has the number or percentage of patients who have tumors are localized increased, and just how unusual is it now to find nonlocalizing studies in ZE patients?
Finally, were the recurrences that you found local disease that could have been removed if the original operation had encompassed more local tissue, or were these liver metastases?
DR. JEFFREY ALLEN NORTON: We still have a significant number of patients with negative imaging studies. We do pancreatic protocol CT, MRI, endoscopic ultrasound, and somatostatin receptor scintigraphy. The studies are not perfect. Some of the patients in this study came from Stanford, where each had all those studies. They are imaging negative and the question comes up whether they should have surgery at all. Dr. Ellison is answering that question differently, but we are recommending surgery because of the results we have shown here.
We stopped doing secretin angiogram because it is both expensive and invasive. Further, the results do not help us plan the operative strategy.
Another question is the mechanism of recurrences. The recurrences are most likely in lymph nodes. A big issue is adequate lymph node sampling. We have tried to do that without doing a Whipple operation. As you know, when you perform a Whipple operation, you get 25 to 30 lymph nodes in the specimen. When we perform a local lymph node sampling, we get approximately three to six. It is most likely inadequate lymph node sampling that explains why there is a higher probability of recurrence.
